Clinical Trial

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each module within this platform study will be provided as appendices to the core protocol.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-03-19; most recent amendment 2026-02-02.
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT06888102
Lead Sponsor Edwin Posadas, MD
Conditions High-risk Prostate Cancer
Enrollment 20 participants
Start Date 2026-04
Primary Completion 2028-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-03